25 results on '"Brugger W"'
Search Results
2. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
3. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
4. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study
5. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: A mature follow-up report
6. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report
7. Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma
8. 993O - OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer: Vistusertib
9. 833P - AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
10. 37 - AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate
11. 1262P - Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
12. 519P - Folfoxiri + Bevacizumab (Bev) in Patients (Pts) with Previously Untreated Metastatic Colorectal Cancer (Mcrc): Final Survival and Pharmacogenomic Profiling Results from the Opal Study
13. 1271P - Analysis of PFS and OS from the Saturn Study According to EGFR IHC Status Using the H-Score Reading Method
14. 9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC
15. 9167 Outcomes with erlotinib in advanced NSCLC: examining the influence of increased EGFR gene copy number and EGFR mutations
16. P110 Pegfilgrastim (Neulasta®) Enables Delivery of FEC 100 Chemotherapy in Elderly Subjects with High Risk Breast Cancer
17. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors
18. Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification
19. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer
20. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer
21. Purging of peripheral blood progenitor cells
22. The management of primary mediastinal B-cell lymphoma with sclerosis
23. 1189 - Evaluation of residual or recurrent malignant lymphoma by FDG-PET
24. Neo-adjuvant high-dose chemotherapy with autologous peripheral blood stem cell transplantation for inoperable relapse of nuchal liposarcoma resistant to standard-dose chemotherapy
25. Peripheral blood progenitor cell transplantation: Where do we stand?: Chairman's summary of the European School of Oncology Task Force Meeting ‘Peripheral Blood Progenitor Cells’ held September 29–30, 1995
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.